Last checked at 28 Jun 2022 15:58
28 June 2022
Futura Medical plc
("Futura" or the "Company")
Futura Medical Announces Annual General Meeting Results
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that at its Annual General Meeting, held today at 10:00am BST, the shareholders duly passed all resolutions.
The total number of votes received on each resolution were as follows:
Voting For | Voting Against | |||||||
Number of votesi | % | Number of votes | % | Total Votes | % ISC | Votes withheldii | ||
Resolution 1 | To accept the Annual Report and accounts | 132,535,568 | 95.80% | 5,769,918 | 4.20% | 138,305,486 | 48.14% | 70,831 |
Resolution 2 | To appoint Jeff Needham as a Director | 138,246,246 | 99.98% | 27,676 | 0.02% | 138,273,922 | 48.13% | 102,395 |
Resolution 3 | To appoint Andrew Unitt as a Director | 138,250,441 | 99.98% | 23,481 | 0.02% | 138,273,922 | 48.13% | 102,395 |
Resolution 4 | To re-elect Ken James as a Director | 138,243,746 | 99.98% | 30,676 | 0.02% | 138,274,422 | 48.13% | 101,895 |
Resolution 5 | To re-appoint Grant Thornton UK LLP as Auditor | 138,244,578 | 99.96% | 49,908 | 0.04% | 138,294,486 | 48.14% | 81,831 |
Resolution 6 | To authorise the Directors to determine the remuneration of Grant Thornton UK LLP | 138,276,015 | 99.97% | 40,471 | 0.03% | 138,316,486 | 48.14% | 59,831 |
Resolution 7 | To authorise the directors of the Company to issue and allot relevant securities (up to 1/3 of the existing issued share capital) pursuant to section 551 of the Companies Act 2006 | 138,239,449 | 99.95% | 65,970 | 0.05% | 138,305,419 | 48.14% | 70,898 |
Resolution 8iii | A Special Resolution empowering the Directors to disapply the pre-emption provision of section 561 of the Act in connection with an offer of equity securities by way of a Rights Issue or up to an aggregate nominal value of £28,729.00 | 138,150,793 | 99.90% | 135,129 | 0.10% | 138,285,922 | 48.13% | 90,395 |
Resolution 9 | A Special Resolution empowering the Directors to disapply the pre-emption provision of section 561 of the Act in connection with an offer of equity securities to fund an acquisition or a capital transaction | 138,170,921
| 99.92% | 111,934 | 0.08% | 138,282,855 | 48.13% | 93,462 |
ⁱ Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution
ⁱⁱ A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution
ⁱⁱⁱ Special Resolution (75% majority required)
The total voting rights of the Company as at 10:00 am on 24 June 2022 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 287,296,527 ordinary shares of 0.2p each. The Company does not hold any shares in treasury
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction ("ED") through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com